PRNewsWire
15 May 2026, 02:20 UTC · 18w ago
Verdict
Headline takes no side. We score QGEN −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 97% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Qiagen is under investigation by Pomerantz LLP for potential securities fraud or other unlawful business practices.
More negative than 96% of claims this week
Qiagen reported a 1% decline in net sales and a 5% decline in QuantiFERON sales on a constant exchange rate basis for Q1 2026.
So whatDeclining top-line revenue, particularly a 5% drop in a key product line, signals deteriorating fundamentals and directly pressures valuations.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 89% of claims this week
Qiagen's stock price fell 10.69% on April 28, 2026, following the release of its preliminary Q1 results.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 97% of ticker scores this week
The company is facing a securities fraud investigation and saw a significant stock price drop following declining sales results.
More negative than 91% of ticker scores this week
The company is the subject of a class action lawsuit.
More negative than 91% of ticker scores this week
The company is under investigation for claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+30.2%
Price is moving against the score
$43.33 vs $33.29 close before publication (May 14) · not market-adjusted
QGEN chart →
